Green Journals

International Approved Journals

Journal Information

Journal Title	Expert Review of Anticancer Therapy
Publisher	Taylor and Francis Ltd.
ISSN	1473-7140
E-ISSN	1744-8328
Database	SCOPUS
Domain	Health Sciences, Life Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies
2026-11-5 Pages 1-10
Authors: Giandomenico Roviello, Kristian Shtembari, Ismaela Anna Vascotto et al.
DOI: 10.1080/14737140.2026.2760188

Biological state–guided oncology: a framework for dynamic precision cancer care through oncological state transitions
2026-11-5
Authors: Takehiro Okabayashi, Ryo Inada, Motoyasu Tabuchi et al.
DOI: 10.1080/14737140.2026.2760189

TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome
2026-11-4 Pages 1-13
Authors: Laura Stanbery, Daniel Craig, Lauren Rager et al.
DOI: 10.1080/14737140.2026.2756200

Survivorship in gynecological cancers: addressing psychosocial and physical challenges
2026-11-3 Pages 1-13
Authors: Hadley W. Reid, Brittany A. Davidson
DOI: 10.1080/14737140.2026.2758536

Uveal melanoma: innovations in therapy, prognosis, and imaging
2026-10-29 Pages 1-19
Authors: Nikhith Rao, Shrihari Nagarajan, Lauren A. Dalvin
DOI: 10.1080/14737140.2026.2755251

Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity
2026-10-29 Pages 1-19
Authors: Shehab F. Mohamed, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali et al.
DOI: 10.1080/14737140.2026.2746616

Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de-intensification strategies
2026-10-15 Pages 1-8
Authors: Martina Catalano, Giandomenico Roviello
DOI: 10.1080/14737140.2026.2749345

Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications
2026-10-11 Pages 1-11
Authors: Alice Costa, Annalisa Astolfi, Livia Gozzellino et al.
DOI: 10.1080/14737140.2026.2746618

How zongertinib was developed for HER2-mutant non-small cell lung cancer: a plain language summary
2026-10-11 Pages 1-8
Authors: John V Heymach, Birgit Wilding
DOI: 10.1080/14737140.2026.2731196

Real-world clinical and economic outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
2026-10-6 Pages 1-11
Authors: Rana R. McKay, Jennifer Nguyen, Barinder Kang et al.
DOI: 10.1080/14737140.2026.2738626